Stockwatch: The Victimization Of Big Biotech
Early Success In Biotech Raises An Almost Impossible Bar
Executive Summary
Alexion is a case study in the travails faced by a biotech with a single blockbuster as it tries to maintain its scale and transform itself into a sustainable business, without blowing billions on bad M&A.
You may also be interested in...
Roche Mounts NMOSD Challenge To Alexion’s Soliris
Satralizumab will be boosted by convenience and MS portfolio in increasingly competitive field.
Stockwatch: Details Differ Between Pfizer And AstraZeneca's Second-Quarter Earnings Reports
Investors in pharmaceutical companies appreciate details such as sales force dynamics, price-volume relationships and channel-stocking effects. Their absence can make investors wary.
Stockwatch: Full-Year 2020 Guidance Separates Novartis And Roche
Pandemic-related clinic closures and safety issues forced Novartis to trim its guidance slightly. But Roche, faced with more severe pandemic and biosimilar pressures, left January’s guidance unchanged.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports